Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer
- PMID: 15725915
- DOI: 10.1097/01.cco.0000155059.39733.9d
Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer
Abstract
Purpose of review: Epidermal growth factor receptor (EGFR) Inhibitors have shown promising results in patients with advanced non-small cell lung cancers (NSCLC) who previously have failed on chemotherapy. Objective response is achieved in 10 to 28% of the patients, and about 30% will achieve stable disease. A major problem is how to select the patients, who will benefit from treatment, and who will not.
Recent findings: The predictive role of EGFR protein expression assessed by IHC is still debated. Specific EGFR gene mutations have been identified associated with response to gefitinib (Iressa(R)), but seem not to be associated with stable disease. No studies have yet demonstrated any association between EGFR gene mutations and survival. In this review we describe other marker studies, which are associated with sensitivity to EGFR inhibitors. Increased EGFR gene copy number based on FISH analysis is demonstrated to be a good predictive marker for response, stable disease, time to progression, and survival.
Summary: EGFR/FISH seems today to be the best predictive marker for clinical benefit from EGFR inhibitors in NSCLC. Prospective large scale clinical studies must identify the most optimal paradigm for selection of patients.
Similar articles
-
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969500 Clinical Trial.
-
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.Int J Cancer. 2005 Jan 1;113(1):109-15. doi: 10.1002/ijc.20550. Int J Cancer. 2005. PMID: 15386420 Clinical Trial.
-
Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy.Ann Oncol. 2007 Mar;18(3):447-52. doi: 10.1093/annonc/mdl407. Epub 2006 Nov 2. Ann Oncol. 2007. PMID: 17082511
-
Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.Curr Drug Targets. 2010 Jul;11(7):851-64. doi: 10.2174/138945010791320773. Curr Drug Targets. 2010. PMID: 20388064 Review.
-
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23. doi: 10.1053/j.semtcvs.2008.09.005. Semin Thorac Cardiovasc Surg. 2008. PMID: 19038731 Review.
Cited by
-
Synthesis, Molecular Docking Study, and Cytotoxic Activity against MCF Cells of New Thiazole-Thiophene Scaffolds.Molecules. 2022 Jul 20;27(14):4639. doi: 10.3390/molecules27144639. Molecules. 2022. PMID: 35889511 Free PMC article.
-
DNA copy number, including telomeres and mitochondria, assayed using next-generation sequencing.BMC Genomics. 2010 Apr 16;11:244. doi: 10.1186/1471-2164-11-244. BMC Genomics. 2010. PMID: 20398377 Free PMC article.
-
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.PLoS Med. 2007 Apr;4(4):e125. doi: 10.1371/journal.pmed.0040125. PLoS Med. 2007. PMID: 17455987 Free PMC article.
-
Synthesis, Biological Evaluation, and Molecular Docking of Novel Azolylhydrazonothiazoles as Potential Anticancer Agents.ACS Omega. 2023 Sep 5;8(37):34044-34058. doi: 10.1021/acsomega.3c05038. eCollection 2023 Sep 19. ACS Omega. 2023. PMID: 37744790 Free PMC article.
-
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.Clin Pharmacokinet. 2011 Jun;50(6):371-403. doi: 10.2165/11587020-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21553932 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
